Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1Phase 1 1

Status

Not yet recruiting 3Unknown 2Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Carcinoma, Hepatocellular 9Esophageal Neoplasms 7Stomach Neoplasms 4Small Cell Lung Carcinoma 4Rectal Neoplasms 4Nasopharyngeal Carcinoma 4Colorectal Neoplasms 4Neoplasms 3Esophageal Squamous Cell Carcinoma 3Colonic Neoplasms 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Hodgkin Disease 2Glioblastoma 2mCRPC 1Uterine Cervical Neoplasms 1Unresectable Stage III Non-small Cell Lung Cancer 1Tongue Squamous Cell Carcinoma 1SCLC, Extensive Stage 1Rare Tumour 1Non-Muscle Invasive Bladder Neoplasms 1Non Squamous Non-small Cell Lung Cancer 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1NSCLC 1MSI-H Colorectal Cancer 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1

Interventions

Exercise 8Standard of Care 5trametinib 3tislelizumab 3Radiotherapy 3Radiosurgery 3Palliative Care 3Paclitaxel 3Gemcitabine 3130-nm albumin-bound paclitaxel 3trastuzumab deruxtecan 2cemiplimab 2Therapeutics 2Surveys and Questionnaires 2Resistance Training 2Oxaliplatin 2Nivolumab 2Maintenance 2Immune Checkpoint Inhibitors 2Drug Therapy 2Cisplatin 2Carboplatin 2vedolizumab 1toripalimab 1surufatinib 1sparsentan 1sintilimab 1semaglutide 1posaconazole 1pomalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Neoplasms × tislelizumab × Clear all
NCT07119996 2025-08-13

Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 1 Not yet recruiting
12 enrolled
Genitourinary

Urinary Bladder Neoplasms, Neoplasms

NCT06456138 2024-06-13

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Shanghai Chest Hospital

Phase 1/2 Not yet recruiting
60 enrolled
Tumor-Agnostic

Neoplasms

NCT06363708 2024-04-12

Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer

Zhongnan Hospital

Phase NA Not yet recruiting
20 enrolled
Gynecologic

Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡